BRPI0410374A - composição farmacêutica que compreende valsartano - Google Patents

composição farmacêutica que compreende valsartano

Info

Publication number
BRPI0410374A
BRPI0410374A BRPI0410374-2A BRPI0410374A BRPI0410374A BR PI0410374 A BRPI0410374 A BR PI0410374A BR PI0410374 A BRPI0410374 A BR PI0410374A BR PI0410374 A BRPI0410374 A BR PI0410374A
Authority
BR
Brazil
Prior art keywords
valsartan
pharmaceutical composition
reducing
pharmaceutically acceptable
mortality
Prior art date
Application number
BRPI0410374-2A
Other languages
English (en)
Inventor
Jay Norman Cohn
Robert Dean Glazer
Robert Latini
Aldo Pietro Maggioni
Gianni Tognoni
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI0410374A publication Critical patent/BRPI0410374A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

"COMPOSIçãO FARMACêUTICA QUE COMPREENDE VALSARTANO". A invenção refere-se a composições farmacêuticas e a método para prevenir ou reduzir a incidência de AF e, desse modo, reduzir o risco de patologia e mortalidade em pacientes com insuficiência cardíaca sintomática, que compreende administrar a esse paciente uma quantidade eficaz de valsartano ou sais farmaceuticamente aceitáveis do mesmo, sozinho ou em combinação com outro agente terapêutico, opcionalmente na presença de um carreador farmaceuticamente aceitável.
BRPI0410374-2A 2003-05-16 2004-05-14 composição farmacêutica que compreende valsartano BRPI0410374A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47113703P 2003-05-16 2003-05-16
PCT/EP2004/005204 WO2004101535A1 (en) 2003-05-16 2004-05-14 Pharmaceutical composition comprising valsartan

Publications (1)

Publication Number Publication Date
BRPI0410374A true BRPI0410374A (pt) 2006-06-13

Family

ID=33452429

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0410374-2A BRPI0410374A (pt) 2003-05-16 2004-05-14 composição farmacêutica que compreende valsartano

Country Status (10)

Country Link
US (2) US20070054947A1 (pt)
EP (1) EP1631556A1 (pt)
JP (1) JP4783733B2 (pt)
CN (1) CN1816533A (pt)
AU (2) AU2004238546A1 (pt)
BR (1) BRPI0410374A (pt)
CA (1) CA2525665A1 (pt)
MX (1) MXPA05012299A (pt)
TW (1) TW200509909A (pt)
WO (1) WO2004101535A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080066776A (ko) * 2005-11-08 2008-07-16 노파르티스 아게 안지오텐신 ⅱ 수용체 봉쇄제, 칼슘 채널 봉쇄제 및 다른활성 약제의 조합물
AR057882A1 (es) 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
WO2012063254A1 (en) * 2010-11-12 2012-05-18 Hetero Research Foundation Novel polymorphs of pitavastatin calcium
JPWO2013147137A1 (ja) * 2012-03-30 2015-12-14 味の素株式会社 心不全の治療剤
EP2887961B1 (en) 2012-08-24 2021-04-28 Novartis AG Nep inhibitors for treating diseases characterized by atrial enlargement or remodeling
PL3626270T3 (pl) * 2013-08-26 2024-04-08 Novartis Ag Leczenie chorób sercowo-naczyniowych
CN106414416B (zh) * 2014-09-09 2020-03-27 上海翰森生物医药科技有限公司 结晶型ARB-NEPi复合物及其制备方法和应用
CA3103599A1 (en) * 2018-06-14 2019-12-19 Astrazeneca Uk Limited Methods for treatment of hypertension with an angiotensin ii receptor blocker pharmaceutical composition
EP3807892A1 (en) * 2018-06-14 2021-04-21 AstraZeneca UK Limited Methods for lowering blood pressure with a dihydropyridine-type calcium channel blocker pharmaceutical composition
CN115317478B (zh) * 2022-08-26 2023-05-02 宁波大学 沙库巴曲缬沙坦类物质在制备药物成瘾和复吸药物的应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6201002B1 (en) * 1997-01-10 2001-03-13 Merck & Co., Inc. Method for reducing mortality with an angiotensin II antagonist
US6204281B1 (en) * 1998-07-10 2001-03-20 Novartis Ag Method of treatment and pharmaceutical composition
EP2322174B1 (en) * 1998-07-10 2015-09-23 Novartis Pharma AG Combined use of valsartan and calcium channel blockers for therapeutic purposes
US6596747B2 (en) * 1998-10-29 2003-07-22 Bristol-Myers Squibb Company Compounds derived from an amine nucleus and pharmaceutical compositions comprising same
CA2360305A1 (en) * 1999-02-09 2000-08-17 Bristol-Myers Squibb Company Lactam inhibitors of fxa and method
US6395728B2 (en) * 1999-07-08 2002-05-28 Novartis Ag Method of treatment and pharmaceutical composition
US6544981B2 (en) * 2000-06-09 2003-04-08 Bristol-Myers Squibb Company Lactam inhibitors of factor Xa and method
AR033390A1 (es) * 2000-08-22 2003-12-17 Novartis Ag Una composicion farmaceutica que comprende un antagonista del receptor at1 y un potenciador de la secrecion de insulina, el uso de dicha composicion para la fabricacion de un medicamento y un kit de partes
CA2428191A1 (en) * 2000-11-07 2002-05-30 Bristol-Myers Squibb Company Acid derivatives useful as serine protease inhibitors
EP1353676A4 (en) * 2000-12-29 2006-05-31 Alteon Inc METHOD FOR THE TREATMENT OF FIBROUS OR OTHER INDICATIONS
US6395782B1 (en) * 2001-03-02 2002-05-28 Wisconsin Alumni Research Foundation Method of increasing longevity and preventing body weight wasting in autoimmune disease by using conjugated linoleic acid
CA2448306A1 (en) * 2001-05-30 2002-12-05 Alteon Inc. Method for treating fibrotic diseases or other indications
EP1448190A2 (en) * 2001-10-18 2004-08-25 Novartis AG Salts formed of an at1-receptor antagonist and a cardiovascular agent
US6869970B2 (en) * 2002-02-04 2005-03-22 Novartis Ag Crystalline salt forms of valsartan
EG24716A (en) * 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds

Also Published As

Publication number Publication date
AU2008246267A1 (en) 2008-12-11
US20070054947A1 (en) 2007-03-08
CN1816533A (zh) 2006-08-09
WO2004101535A1 (en) 2004-11-25
JP2006528949A (ja) 2006-12-28
TW200509909A (en) 2005-03-16
AU2004238546A1 (en) 2004-11-25
EP1631556A1 (en) 2006-03-08
MXPA05012299A (es) 2006-01-30
CA2525665A1 (en) 2004-11-25
JP4783733B2 (ja) 2011-09-28
US20090105322A1 (en) 2009-04-23
AU2008246267B2 (en) 2011-02-17

Similar Documents

Publication Publication Date Title
AR038605A1 (es) Uso de agentes para la manufactura de un medicamento para el tratamiento de inflamacion y composiciones para dicho tratamiento
ATE355065T1 (de) Therapeutische zusammensetzungen bestehend aus antihypotensiva und antiangiogenika
EA200800056A1 (ru) Каннабиноидный активный фармацевтический ингредиент для лекарственных форм
ES2164040T1 (es) Uso de agonistas del sitio de union de la glicina o de inhibidores de la absorcion de la glicina para el tratamiento de trastornos neuropsiquiatricos.
BRPI0519656A2 (pt) terapia de combinaÇço compreendendo telmisartan e hidroclorotiazida
BRPI0414565A (pt) composições farmacêuticas e métodos que compreendem combinações de derivados de 2-alquilideno-19-nor-vitamina d e um bisfosfonato
RU2008119454A (ru) Лекарственное средство для защиты моторного нейрона у пациентов с боковым амиотрофическим склерозом
AR074313A1 (es) Metodo para tratar o prevenir la trombosis utilizando etexilato de dabigatran o una sal del mismo. uso. kit
RS52867B (en) GLATIRAMER ACETATOM AND RAZAGILIN COMBINED THERAPY FOR MULTIPLE SCLEROSIS
RS54050B1 (en) FORMULATIONS AND METHODS FOR THE TREATMENT OF AMYLOIDOSIS
BRPI0408655A (pt) formulações compreendendo um agente ativo e cacau em pó e a sua utilização
BR9914419A (pt) Terapia para melhoria da percepção
ES2570401T3 (es) Métodos de tratamiento usando dosis únicas de oritavancina
BRPI0414500A (pt) formulação farmacêutica composição para tratar uma infecção vaginal, e, métodos para tratar uma infecção vaginal, para estabilizar uma formulação de clindamicina, para tratar ou prevenir uma recorrência de uma infecção vaginal em uma paciente e para tratar condições vaginais
AU2002231889A1 (en) Halogenated composition, method for preparing same and uses thereof
BR112013010829B8 (pt) Composição farmacêutica intravenosa para proporcionar alívio da dor e/ou da inflamação
BRPI0410374A (pt) composição farmacêutica que compreende valsartano
AR048318A1 (es) Formulaciones de matriz orales que comprenden licarbazepina
BRPI0414305A (pt) sistema de liberação de drogas por via oral
BR0313413A (pt) Uso da vacinação beta amilóide juntamente com um inibidor da cox-2 seletivo para o tratamento da doença de alzheimer
MXPA04007183A (es) Composicion farmaceutica para el control de la glucosa en sangre de pacientes con diabetes tipo 2.
BR0310061A (pt) Métodos para o tratamento de doenças e condições respiratórias com um inibidor seletivo da inos e um inibidor da pde e suas composições
BRPI0519036A2 (pt) mÉtodo para o tratamento de um paciente acometido por uma doenÇa neuro-degenerativa; composiÇço farmacÊutica para tratar uma doenÇa neuro-degenerativa; e uso de um agonista 5-ht6 ou de um agonista 5-ht6
BR0313411A (pt) Uso de reboxetina para o tratamento de ondas de calor
BRPI0409699A (pt) métodos de indução do efeito diurético, de indução, manutenção ou restauração do efeito diurético de diurético não modificador de adenosina, de manutenção, restauração ou melhoria da função renal em paciente, de indução de diurese, de prevenção do inìcio de deficiência renal em paciente com sobrecarga de fluidos ou chf, de tratamento de paciente que sofre de chf e de melhoria dos resultados globais da saúde, composição farmacêutica e seus usos

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08L Patent application lapsed because of non payment of annual fee [chapter 8.12 patent gazette]

Free format text: REFERENTE AO NAO RECOLHIMENTO DAS 9A E 10A ANUIDADES.

B08I Publication cancelled [chapter 8.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 8.12 NA RPI NO 2258 DE 15/04/2014 POR TER SIDO INDEVIDA.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 9A, 10A, 11A, 12A, 13A, 14A, 15A E 16A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2602 DE 17-11-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.